A Study of IBI306 in Participants With Hypercholesterolemia
Status:
Recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
This study is designed for multi-center, double-blind, randomized, placebo-controlled phase
III trial to evaluate the safety and tolerability of subcutaneous injection of IBI306 in
hypercholesterolemia patients.